Welcome to our dedicated page for Abcellera Biologics news (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on Abcellera Biologics stock.
AbCellera Biologics Inc. (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women’s health, immunology, and oncology. The ABCL news feed on Stock Titan aggregates company announcements, clinical updates, financial disclosures, and other material events drawn from AbCellera’s press releases and regulatory filings.
Investors and followers of ABCL can use this page to review news on AbCellera’s internal pipeline, including its lead programs ABCL635 and ABCL575. Recent announcements describe ABCL635 as a potential first-in-class non-hormonal antibody treatment for moderate-to-severe vasomotor symptoms associated with menopause, now in a Phase 1/2 clinical trial, and ABCL575 as an Fc-silenced, half-life extended investigational antibody therapy in a Phase 1 study for moderate-to-severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions.
The ABCL news stream also captures business and corporate developments, such as quarterly business results, updates on partner-initiated programs and molecules in the clinic, and changes in leadership and board composition. In addition, it includes disclosures on legal and intellectual property matters, including AbCellera’s settlement and patent license agreement with Bruker Corporation that resolved patent litigation globally and provides for upfront and royalty payments.
By reviewing this curated news page, readers can follow how AbCellera advances its antibody discovery and development engine, expands its clinical-stage pipeline, and manages its partnered programs and intellectual property. Bookmark this ABCL news section to quickly access company-issued updates, earnings announcements, clinical trial milestones, and other material information relevant to AbCellera’s operations and strategy.
AbCellera (Nasdaq: ABCL) has appointed Neil Berkley as Chief Business Officer, focusing on expanding its partnership business, which includes over 100 programs with various drug developers. With over 20 years of experience in business development, Berkley aims to leverage partnerships for accelerating antibody therapeutics development. His prior roles include leadership positions at Halozyme Therapeutics and Acadia Pharmaceuticals. CEO Carl Hansen expressed enthusiasm for Berkley's role in enhancing the company’s global reach and strategic growth.
AbCellera (ABCL) has announced plans to build a 130,000-square-foot GMP manufacturing facility in Vancouver, marking a significant expansion in Canada’s capacity to produce therapeutic antibodies. This facility, set for completion in early 2024, aims to enhance AbCellera’s role in accelerating antibody therapies from discovery to clinical trials. The project is partly funded by a US$125.6 million grant from the Canadian government. AbCellera expects to add hundreds of jobs, contributing to improved pandemic preparedness and economic recovery in Canada.
AbCellera (Nasdaq: ABCL) announced that certain entities owned by CEO Carl Hansen and other senior leaders sold 11,900,000 common shares to institutional investors. The sale, attributed to estate planning and charitable giving, did not provide proceeds to AbCellera, and Dr. Hansen retains 20% equity interest. After the sale, the Selling Shareholders hold around 89% of their equity, representing about 30% of fully diluted shares. A Registration Statement on Form S-1 was filed on June 10, 2021, to register the Shares.
AbCellera (ABCL) reported Q1 2021 financial results, showcasing a remarkable 4253% increase in total revenue, reaching $202.7 million compared to $4.7 million in Q1 2020. Key highlights include $171.5 million in royalty revenue from bamlanivimab and $117.2 million in net earnings, a significant recovery from a $2.1 million loss the previous year. The company expanded its partnership portfolio, achieving 119 programs under contract with 29 partners. R&D expenses rose to $12.4 million, reflecting robust investments in discovery capabilities.
AbCellera (Nasdaq: ABCL) has announced that its executives will present virtually at the Berenberg Conference USA 2021 on May 18, 2021, at 11:00 a.m. Pacific Time. A live audio webcast will be available through AbCellera’s Investor Relations website, with a replay accessible afterward.
AbCellera is a technology company focused on analyzing natural immune systems to discover antibodies for drug development. The company supports both large pharmaceutical and small biotechnology partners, enabling efficient and cost-effective drug development.
AbCellera (Nasdaq: ABCL) and Angios GmbH have announced a multi-year collaboration focused on discovering monoclonal and bispecific antibodies for eye vascular diseases, particularly diabetic retinopathy. AbCellera will leverage its AI-powered platform to create antibody panels for up to three targets selected by Angios. This partnership allows Angios to expedite their therapeutic development efforts without the need for extensive internal resources. Under the agreement, Angios will retain rights to develop and commercialize resulting therapies, while AbCellera will receive equity, research fees, milestone payments, and royalties.
AbCellera (Nasdaq: ABCL) announced that its second antibody, LY-CoV1404, has commenced clinical trials for treating patients with mild-to-moderate COVID-19. The ongoing BLAZE-4 trials, conducted with Eli Lilly, will assess LY-CoV1404 both solo and in combination with other antibodies. Preclinical results demonstrate that LY-CoV1404 effectively binds to a stable region of the SARS-CoV-2 spike protein, neutralizing all known variants of concern. This potent antibody may enable lower clinical dosing and potentially subcutaneous administration, supporting its role in combating COVID-19 long-term.
AbCellera (Nasdaq: ABCL) has commenced construction on an expanded global headquarters in Vancouver, aiming to grow its workforce from 250 to hundreds over the next few years. The new tech campus will span 380,000 square feet and is projected for completion in 2023 and 2024. CEO Carl Hansen emphasized that the facilities will accelerate antibody therapy development in collaboration with global biotech and pharma partners. This development solidifies Vancouver's position as an innovation hub and supports AbCellera's long-term goal of establishing Canada's first clinical-grade antibody manufacturing facility.
AbCellera (Nasdaq: ABCL) will release its first-quarter 2021 financial results on May 13, 2021, and host an earnings conference call at 2:00 p.m. PT (5:00 p.m. ET). A live webcast will be accessible via the Investor Relations website, with a replay available afterward.
AbCellera specializes in antibody discovery by analyzing immune systems, partnering with various drug developers to streamline drug development processes.
AbCellera (Nasdaq: ABCL) and Empirico Inc. announced a strategic collaboration focusing on multi-target drug discovery. The partnership utilizes advanced technologies and data analysis to identify therapeutic targets and antibodies. Empirico will select up to five targets using its Precision Insights Platform, while AbCellera will leverage its AI for antibody discovery. AbCellera will receive research payments and may earn royalties from developed products. The collaboration aims to address challenges in drug development by linking human genetics to therapy insights.